Compounds > arginine

arginine and Neuroendocrine Tumors

arginine has been researched along with Neuroendocrine Tumors in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (40.00)29.6817
2010's1 (20.00)24.3611
2020's2 (40.00)2.80

Authors

AuthorsStudies
Brillouet, S; Chatelut, E; Courbon, F; Dierickx, L; Lambert, M1
Al-Toubah, T; Bottiglieri, S; El-Haddad, G; Hutchinson, T; Jesurajan, J; Pellé, E; Sikaria, D; Smith, J; Strosberg, J1
Bedossa, P; Couvelard, A; Cros, J; de Mestier, L; Guedj, N; Hammel, P; Hentic, O; Moati, E; Panis, Y; Paradis, V; Raffenne, J; Ruszniewski, P; Sauvanet, A; Sbidian, E; Svrcek, M1
de Jong, M; Kooij, PP; Krenning, EP; Rolleman, EJ; Valkema, R1
Barone, R; Bouterfa, H; Carlier, P; Chen, T; de Camps, J; Jamar, F; Krenning, EP; Kvols, LK; Labar, D; Mathieu, I; Pauwels, S; Schran, H; Smith, MC; Valkema, R; Walrand, S1

Trials

2 trial(s) available for arginine and Neuroendocrine Tumors

ArticleYear
Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine.
    European journal of nuclear medicine and molecular imaging, 2003, Volume: 30, Issue:1

    Topics: Arginine; Carcinoma, Neuroendocrine; Female; Humans; Hyperkalemia; Infusions, Intravenous; Kidney; Lysine; Neuroendocrine Tumors; Octreotide; Pentetic Acid; Radionuclide Imaging; Radiopharmaceuticals; Vomiting

2003
86Y-DOTA0)-D-Phe1-Tyr3-octreotide (SMT487)--a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion.
    European journal of nuclear medicine and molecular imaging, 2003, Volume: 30, Issue:4

    Topics: Adult; Aged; Amino Acids; Arginine; Cohort Studies; Cross-Over Studies; Dizziness; Drug Combinations; Female; Humans; Infusions, Intravenous; Kidney; Lysine; Male; Metabolic Clearance Rate; Middle Aged; Neuroendocrine Tumors; Octreotide; Organ Specificity; Radiation Dosage; Radiation Injuries; Radiation-Protective Agents; Radiometry; Radiopharmaceuticals; Tissue Distribution; Tomography, Emission-Computed; Vomiting; Yttrium Radioisotopes

2003

Other Studies

3 other study(ies) available for arginine and Neuroendocrine Tumors

ArticleYear
Comparison of Two Types of Amino Acid Solutions on
    Current radiopharmaceuticals, 2022, Volume: 15, Issue:2

    Topics: Arginine; Humans; Intestinal Neoplasms; Lysine; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Pancreatic Neoplasms; Positron-Emission Tomography; Radionuclide Imaging; Radiopharmaceuticals; Stomach Neoplasms

2022
Comparison of Nausea and Vomiting Associated With Amino Acid Formulations Coinfused With Peptide Receptor Radionuclide Therapy: Commercial Parenteral Nutrition Formulas Versus Compounded Arginine/Lysine.
    Pancreas, 2021, 04-01, Volume: 50, Issue:4

    Topics: Aged; Aged, 80 and over; Amino Acids; Arginine; Combined Modality Therapy; Female; Humans; Infusion Pumps; Lysine; Male; Middle Aged; Nausea; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Outcome Assessment, Health Care; Parenteral Nutrition; Radiopharmaceuticals; Receptors, Peptide; Retrospective Studies; Vomiting

2021
Gly388Arg FGFR4 Polymorphism Is Not Predictive of Everolimus Efficacy in Well-Differentiated Digestive Neuroendocrine Tumors.
    Neuroendocrinology, 2016, Volume: 103, Issue:5

    Topics: Aged; Antineoplastic Agents; Arginine; Digestive System Neoplasms; Everolimus; Female; Gene Expression Regulation, Neoplastic; Genotype; Glycine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neuroendocrine Tumors; Polymorphism, Single Nucleotide; Receptor, Fibroblast Growth Factor, Type 4; Retrospective Studies; Signal Transduction; STAT3 Transcription Factor

2016